Aktis Oncology, Inc. (AKTS) Insider Trading
Directors, officers and holders of more than 10% of AKTS report their trades in its stock on SEC Form 4, within two business days. Each row below is one Form 4 transaction line. The one-letter code says what kind of transaction it was: only P (purchase) and S (sale) are open-market or private trades; awards, option exercises, tax withholding and gifts carry other codes.
Recent Form 4 transactions
The 50 most recent of 76 transactions on file: 1 with code P, 11 with code S and 38 with other codes.
| Date | Insider | Title | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | Czibere Akos | Chief Medical Officer | S Sale | 7,401 | $21.03 | $155,648 |
| Sep 23, 2026 | Czibere Akos | Chief Medical Officer | M Exercise | 12,500 | $4.95 | $61,875 |
| Sep 23, 2026 | Czibere Akos | Chief Medical Officer | S Sale | 5,099 | $20.19 | $102,973 |
| Sep 23, 2026 | Czibere Akos | Chief Medical Officer | M Exercise | 12,500 | Not measured | Not measured |
| Jul 20, 2026 | Herrmann Ken | Director | M Exercise | 3,506 | Not measured | Not measured |
| Jul 20, 2026 | Herrmann Ken | Director | M Exercise | 3,506 | $0.0800 | $280 |
| Jul 20, 2026 | Herrmann Ken | Director | M Exercise | 1,350 | $1.91 | $2,579 |
| Jul 20, 2026 | Herrmann Ken | Director | M Exercise | 1,350 | Not measured | Not measured |
| Jul 20, 2026 | Herrmann Ken | Director | S Sale | 3,506 | $24.56 | $86,115 |
| Jul 20, 2026 | Herrmann Ken | Director | S Sale | 1,350 | $24.56 | $33,159 |
| Jul 17, 2026 | Herrmann Ken | Director | M Exercise | 3,065 | $0.0800 | $245 |
| Jul 17, 2026 | Herrmann Ken | Director | M Exercise | 3,065 | Not measured | Not measured |
| Jul 17, 2026 | Herrmann Ken | Director | S Sale | 3,065 | $25.21 | $77,259 |
| Jul 8, 2026 | Czibere Akos | Chief Medical Officer | S Sale | 30,829 | $27.95 | $861,735 |
| Jul 8, 2026 | Ron-Bigger Shulamit | Chief Operating Officer | M Exercise | 50,000 | $3.66 | $183,000 |
| Jul 8, 2026 | Ron-Bigger Shulamit | Chief Operating Officer | S Sale | 15,800 | $27.13 | $428,681 |
| Jul 8, 2026 | Ron-Bigger Shulamit | Chief Operating Officer | S Sale | 30,000 | $27.94 | $838,137 |
| Jul 8, 2026 | Ron-Bigger Shulamit | Chief Operating Officer | S Sale | 4,200 | $28.75 | $120,740 |
| Jul 8, 2026 | Czibere Akos | Chief Medical Officer | M Exercise | 50,000 | $4.95 | $247,500 |
| Jul 8, 2026 | Ron-Bigger Shulamit | Chief Operating Officer | M Exercise | 50,000 | Not measured | Not measured |
| Jul 8, 2026 | Czibere Akos | Chief Medical Officer | S Sale | 4,371 | $28.71 | $125,482 |
| Jul 8, 2026 | Czibere Akos | Chief Medical Officer | S Sale | 14,800 | $27.13 | $401,484 |
| Jul 8, 2026 | Czibere Akos | Chief Medical Officer | M Exercise | 50,000 | Not measured | Not measured |
| Apr 15, 2026 | Gormley Glenn | Director | A Award | 37,866 | Not measured | Not measured |
| Jan 12, 2026 | MPM BIOVENTURES 2018, L.P. | 10% Owner | C Conversion | 1,577,119 | Not measured | Not measured |
| Jan 12, 2026 | MPM BIOVENTURES 2018, L.P. | 10% Owner | P Purchase | 1,112,777 | $18.00 | $20,029,986 |
| Jan 12, 2026 | EcoR1 Capital, LLC | Director | C Conversion | 9,913,810 | Not measured | Not measured |
| Jan 12, 2026 | EcoR1 Capital, LLC | Director | C Conversion | 997,299 | Not measured | Not measured |
| Jan 12, 2026 | EcoR1 Capital, LLC | Director | C Conversion | 488,891 | Not measured | Not measured |
| Jan 12, 2026 | EcoR1 Capital, LLC | Director | C Conversion | 2,397,500 | Not measured | Not measured |
| Jan 12, 2026 | EcoR1 Capital, LLC | Director | C Conversion | 102,500 | Not measured | Not measured |
| Jan 12, 2026 | EcoR1 Capital, LLC | Director | C Conversion | 965,190 | Not measured | Not measured |
| Jan 12, 2026 | EcoR1 Capital, LLC | Director | C Conversion | 86,222 | Not measured | Not measured |
| Jan 12, 2026 | Vida Ventures II, LLC | 10% Owner | C Conversion | 14,838,250 | Not measured | Not measured |
| Jan 12, 2026 | Vida Ventures II, LLC | 10% Owner | C Conversion | 411,750 | Not measured | Not measured |
| Jan 12, 2026 | Vida Ventures II, LLC | 10% Owner | C Conversion | 3,648,750 | Not measured | Not measured |
| Jan 12, 2026 | Vida Ventures II, LLC | 10% Owner | C Conversion | 101,250 | Not measured | Not measured |
| Jan 12, 2026 | Segal Lloyd Mitchell | Director | C Conversion | 50,000 | Not measured | Not measured |
| Jan 12, 2026 | Segal Lloyd Mitchell | Director | C Conversion | 24,687 | Not measured | Not measured |
| Jan 12, 2026 | Kim Helen Susan | Director | C Conversion | 14,838,250 | Not measured | Not measured |
| Jan 12, 2026 | Kim Helen Susan | Director | C Conversion | 411,750 | Not measured | Not measured |
| Jan 12, 2026 | Kim Helen Susan | Director | C Conversion | 3,648,750 | Not measured | Not measured |
| Jan 12, 2026 | Kim Helen Susan | Director | C Conversion | 101,250 | Not measured | Not measured |
| Jan 12, 2026 | EcoR1 Capital, LLC | Director | C Conversion | 2,270,879 | Not measured | Not measured |
| Jan 12, 2026 | GADICKE ANSBERT | 10% Owner | C Conversion | 22,500,000 | Not measured | Not measured |
| Jan 12, 2026 | GADICKE ANSBERT | 10% Owner | C Conversion | 6,000,000 | Not measured | Not measured |
| Jan 12, 2026 | Foley Todd | Director | C Conversion | 2,272,727 | Not measured | Not measured |
| Jan 12, 2026 | Foley Todd | Director | C Conversion | 10,227,273 | Not measured | Not measured |
| Jan 12, 2026 | Foley Todd | Director | C Conversion | 2,727,273 | Not measured | Not measured |
| Jan 12, 2026 | MPM BIOVENTURES 2018, L.P. | 10% Owner | C Conversion | 5,000,000 | Not measured | Not measured |
The full Form 4 history is on the AKTS company page (Insider Trades card, View all).
Questions about this data
Which insider transactions are open-market trades?
Code P (open market or private purchase) and code S (open market or private sale). Code F is shares withheld to pay tax on vesting stock, A is an award from the company, M and X are option exercises and G is a gift. None of those is the insider choosing to buy or sell in the market.
How quickly are insider trades reported?
A Form 4 is due before the end of the second business day after the trade. The date shown is the transaction date from the form.
Who has to file Form 4?
Officers, directors and beneficial owners of more than 10% of a class of the company’s registered equity, under Section 16 of the Securities Exchange Act.
Look up any code in the Form 4 transaction code reference, or read Form 4 codes explained.